Related Experiment Videos
Protein Z influences the prothrombotic phenotype in Factor V Leiden patients
Bettina Kemkes-Matthes1, Margareta Nees, Gitta Kühnel
1Zentrum für Innere Medizin der Justus Liebig Universität Giessen, Klinikstrasse 36, D-35385 Giessen, Germany. Bettina.Kemkes-Mathes@innere.med.uni-giessen.de
Abstract:
Protein Z enhances the inhibition of factor Xa by protein Z-dependent protease inhibitor (ZPI). Thus, diminution of protein Z should induce prothrombotic tendency due to lowered cofactor activity for ZPI. In Factor V Leiden mice, prothrombotic tendency of severe diminution or lack of protein Z was demonstrated. We here present first studies in humans, indicating that diminution of protein Z in factor V Leiden patients aggravates thromboembolic risk.
Insights
Reduced protein Z levels worsen blood clot risk in Factor V Leiden patients. This study shows lower protein Z exacerbates thrombosis in humans, unlike in mice.
Area of Science:
- Biochemistry
- Hematology
- Thrombosis Research
Background:
- Protein Z is a cofactor for protein Z-dependent protease inhibitor (ZPI).
- ZPI inhibits coagulation factor Xa, regulating blood clot formation.
- Diminished protein Z is hypothesized to increase thrombotic risk due to reduced ZPI activity.
Purpose of the Study:
- To investigate the role of protein Z in human thromboembolic risk.
- To determine if protein Z deficiency exacerbates risk in Factor V Leiden patients.
Main Methods:
- Observational study in human patients.
- Analysis of protein Z levels in relation to thromboembolic events.
- Comparison with findings in Factor V Leiden mouse models.
Main Results:
- Severe deficiency or absence of protein Z demonstrated prothrombotic tendency in Factor V Leiden mice.
- First human data indicate that diminished protein Z aggravates thromboembolic risk in Factor V Leiden patients.
Conclusions:
- Protein Z plays a crucial role in regulating thrombosis in humans.
- Factor V Leiden patients with low protein Z have an increased risk of blood clots.